NEW YORK (GenomeWeb) – Genetic testing company Invitae has expanded its next-generation sequencing-based assay to 600 genes from 200 genes and added new diagnostic panels in the areas of cardiovascular disease, hereditary cancer, neuromuscular disorders, rare disease, and pediatric disease, the company said today.

In addition, the firm struck an agreement with the Blue Cross Blue Shield Association this week that allows it to negotiate with individual plans for in-network status.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.